Exciting new treatment for diffuse-large B-cell lymphoma approved by the European Medicines Agency (EMA).

In July 2023 the EMA approved Glofitamab, one of the most potent single drugs available for the treatment of relapsed/refractory DLBCL.

Glofitamab is a CD20xCD3 bispecific T-cell engager. In a Phase 2 trial of 108 relapsed/refractory DLBCL patients who received glofitamab for a fixed duration an overall response was seen in 50% and a complete response in 35% of patients.